ThePeptide.expert
This information is for research and educational purposes only. This is not medical advice.
← All profiles
Cat 1 — 2026RecoveryImmune

BPC-157

Body Protection Compound-157

15-amino acid peptide derived from human gastric juice. Promotes tissue repair, gut healing, and angiogenesis. Among the most-researched repair peptides available.

Evidence
Strong clinical data
Routes
injectable, oral
Available since
Early 2000s (research); 2020s (clinical compounding access)

Mechanism of action

Activates VEGF and EGF growth factor pathways, promotes angiogenesis (new blood vessel formation), upregulates nitric oxide synthesis, and modulates the GABAergic system. Accelerates collagen synthesis and tendon-to-bone healing by stimulating tendon fibroblasts.

Effects in the body

BPC-157 acts as a master repair signal throughout the body. It accelerates healing in tendons, ligaments, muscles, and gut lining. Uniquely, it shows systemic effects even when taken orally — one of the few peptides where oral administration reaches therapeutic targets for gut-specific research.

Pros & cons (from the literature)

Pros
  • Strong tendon and ligament repair data in preclinical models
  • Gut healing studied in IBD and leaky gut animal models
  • Anti-inflammatory and neuroprotective properties
  • Oral AND injectable administration both studied
  • Extremely well-tolerated in 300+ animal studies
Cautions
  • No completed Phase III human RCTs
  • Theoretical cancer promotion via angiogenesis
  • Gray-market purity varies widely (60–85% common vs 98%+ pharmaceutical grade)
  • Optimal human dosing not established
  • Long-term human safety unknown

Protocol summary (from published research)

Injectable: 200–400 mcg/day subcutaneous or intramuscular near injury site. 4–6 week research cycles. Oral (gut research): 500–1000 mcg/day on empty stomach. Frequently studied alongside TB-500 for synergistic tissue repair.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Returned to Category 1 in February 2026 under HHS directive. Can be compounded by licensed 503A pharmacies with a physician prescription. Not FDA-approved as a drug.

Evidence base

Sikiric et al. published 300+ papers. Phase I/II trials ongoing as of 2026. No Phase III completion. Extensive preclinical data across multiple tissue types.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Expert perspective — Dr. Alex Tatem, Urologist

Dr. Alex Tatem is a board-certified Urologist and Men's Health Specialist who has studied peptides for 12 years. Videos featured for educational purposes. ThePeptide.expert is an independent platform.

Dr. Tatem explains BPC-157, TB-500, and the 2026 FDA peptide landscape — including why these compounds were restricted and what the regulatory reversal means for researchers.

Pro member exclusive

Significant savings on research-grade peptides at a licensed, quality-controlled supplier

Your Pro membership includes an exclusive discount code for 99%+ purity verified research peptides at the best available price, from a licensed supplier we have evaluated for purity standards and compliance. Plus curated guides so you know exactly what to research.

  • • Exclusive discount code included with Pro membership
  • • Curated guide for this specific peptide
  • • Verified 99%+ purity compounds
  • • Removes the guesswork entirely
Upgrade to Pro — $15/month

Cancel anytime · No long-term commitment

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.